Yen‐Hao Chen

机构：Chang Gung University, Kaohsiung Chang Gung Memorial Hospital · ORCID：0000-0002-5622-5490

发表论文 119 篇 · 总被引 2316 次 · h-index 21

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study (2023 · The Lancet · 被引 704)
• Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma (2023 · BMC Cancer · 被引 19)
• Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy (2024 · Hepatology International · 被引 16)
• Preoperative neutrophil–to–lymphocyte ratio after chemoradiotherapy for esophageal squamous cell carcinoma associates with postoperative pulmonary complications following radical esophagectomy (2024 · Perioperative Medicine · 被引 5)
• Number of Retrieved Lymph Nodes during Esophagectomy Affects the Outcome of Stage III Esophageal Cancer in Patients Having Had Pre-Operative Chemo-Radiation Therapy (2024 · Current Oncology · 被引 4)
• Similar survival after endoscopic submucosal dissection and esophagectomy in early esophageal cancer and synchronous or metachronous head and neck cancer (2024 · Journal of Cardiothoracic Surgery · 被引 4)